References
- Beham AW, Schaefer I-M, Schüler P, et al. Gastrointestinal stromal tumors. Int J Colorectal Dis 2012;27:689-700
- Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010;8(2 Suppl):S1-41; quiz S42–4. http://www.ncbi.nlm.nih.gov/pubmed/20457867. Accessed on November 27, 2014
- DeMatteo RP, Lewis JJ, Leung D, et al. Two Hundred Gastrointestinal Stromal Tumors. Ann Surg 2000;231:51-58
- Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097-104
- Essat M, Cooper K. Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review. Int J Cancer 2011;128:2202-14
- Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012;307:1265-72
- Cohen MH, Johnson JR, Justice R, et al. Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors. Oncologist 2012;17:992-7
- Conley AP, Guerin A, Sasane M, et al. Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients-a chart extract-based approach. J Gastrointest Cancer 2014;45:431-40
- Rubin JL, Sanon M, Taylor DC, et al. Epidemiology, survival, and costs of localized gastrointestinal stromal tumors. Int J Gen Med 2011;4:121-30
- Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27. http://www.ncbi.nlm.nih.gov/pubmed/9431328. Accessed September 17, 2013
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). 5th ed. Arlington, VA: American Psychiatric Publishing, 2013
- Conley AP, Guérin A, Sasane M, et al. Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach. J Gastrointest Cancer 2013;44:190-8
- Hatoum HT, Lin S-J, Sasane M, et al. Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor: results of a population-based, matched-cohort study. Curr Med Res Opin 2012;28:805-14
- Blay J-Y, von Mehren M, Blackstein ME. Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer 2010;116:5126-37